AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06635044 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intradialytic exercise
Description: HD men came to the HD unit three times weekly to receive their dialysis session which consumed 3-4 hours. During the first two hours of the men's dialysis session, a pedal exerciser (RTL10273 Deluxe Folding Pedal Exerciser, Drive Medical Co. MPN) was utilized in performing leg cycling exercises while men were sitting. Before starting the session of intradialytic cycling, a 5-minute stretching of the lower limbs was performed as a warming up. Also, as cooling down, the same period of lower limbs' stretching was performed after ending intradialytic cycling
Study NCT06635967 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: frequency-specific rTMS
Description: Patterned repetitive transcranial magnetic stimulation will be performed at specific frequencies and inter-train intervals
Study NCT06635967 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 1 Hz rTMS
Description: Low-frequency rTMS will be performed at a frequency of 1Hz
Study NCT06636188 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digi-Coach Chatbot
Description: Participants will have access to the Digi-Coach chatbot in addition to usual care. The research nurse will provide training on how to navigate the chatbot and ask participants to query all their cancer related concerns in the chatbot.
Study NCT06635707 — intervention group
Intervention type: DRUG
Intervention: Urapidil
Description: 1. Control systolic blood pressure within 130-140mmHg using urapidil and maintain this level for 7 days;~2. Reduce intracranial pressure through dehydration therapy with mannitol, positioning of the body, and other means to prevent cerebral hernia. Surgical interventions such as decompressive craniectomy may be performed if necessary;~3. Aim for a body temperature control target of ≤37.5°C;~4. The anticoagulation reversal target is INR \< 1.5, with correction methods including the use of vitamin K, prothrombin complex concentrate (PCC), or fresh frozen plasma (FFP);~5. The blood glucose control targets are 6.1-7.8mmol/L for non-diabetic study participants and 7.8-10.0mmol/L for diabetic study participants.
Study NCT06635707 — intervention group
Intervention type: DRUG
Intervention: Urapidil and Esmolol
Description: 1. Utilize both urapidil and esmolol to control systolic blood pressure within 130-140mmHg and maintain this level for 7 days;~2. Reduce intracranial pressure through dehydration therapy with mannitol, strategic positioning of the body, and other measures to prevent cerebral hernia. Surgical interventions such as decompressive craniectomy may be performed if necessary;~3. Aim for a body temperature control target of ≤37.5°C;~4. The anticoagulation reversal target is INR \< 1.5, with correction methods including the administration of vitamin K, prothrombin complex concentrate (PCC), or fresh frozen plasma (FFP);~5. The blood glucose control targets are 6.1-7.8mmol/L for non-diabetic study participants and 7.8-10.0mmol/L for diabetic study participants.
Study NCT06364657 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Eye Exam
Description: * Symptom Questionnaires (OSDI, eye dryness VAS, visual fatigue VAS, eye discomfort VAS)~* Pain scale questionnaire \[Wong-Baker Faces Pain Rating Scale and Ocular Pain Assessment Survey~* Best spectacle-corrected visual acuity (BSCVA) as measured by Snellen chart followed by Mars contrast sensitivity test.~* Corneal esthesiometer for measurement of corneal sensation~* Schirmer's without topical anesthesia~* Corneal epithelial thickness sand endothelial cell count using Anterior Segment Optical Coherence Tomography (AS-OCT)~* Staining for dry eye:~* Tear film break-up time (BUT) using fluorescein.~* Fluorescein staining (National Eye Institute (NEI) and Ocular staining score (OSS))~* Lissamine green staining (OSS and Oxford)~* Non-contact confocal biomicroscopy for morphology of the ocular surface
Study NCT05556772 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Collection of blood; urine; cervical, anal, vaginal samples
Study NCT05556772 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Attend interview
Study NCT06285383 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music listening
Description: Participants will listen to the music pieces Pachabel Canon in D major (30 minutes), free from external sounds (max 70 dB through headphones).
Study NCT06285383 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: classic physical therapy
Description: classic physical therapy
Study NCT06285383 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: classic physical therapy
Description: classic physical therapy
Study NCT06715163 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dose 1 (42mg) of DAO
Description: DAO extract is obtained from pea sprout dehydrated powder. Lowest dose of DAO administered in this study
Study NCT06529224 — intervention group
Intervention type: OTHER
Intervention: Online questionnaire
Description: An online questionnaire will be distributed in electronic format to all the healthcare professionals concerned.
Study NCT05608187 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ILP100-Topical (emilimogene sigulactibac) 5x10^7 CFU/cm^2
Description: Topical application of ILP100-Topical (emilimogene sigulactibac) at a dose of 5x10\^7 CFU/cm\^2 wound area.
Study NCT05608187 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ILP100-Topical (emilimogene sigulactibac) 1x10^9 CFU/cm^2
Description: Topical application of ILP100-Topical (emilimogene sigulactibac) at a dose of 1x10\^9 CFU/cm\^2 wound area.
Study NCT05608187 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical application of placebo (ILP100 dilution buffer mixed with the activation peptide SppIP).
Study NCT05443620 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Weight vest
Description: A vest weighing up to a maximum of 15 kg.
Study NCT05443620 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Wheelchair
Description: Wheelchair in which participants will be sitting to reduce loading on lower extremities.
Study NCT04441047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AlloStim
Description: Living, activated allogeneic Th1-like memory immune cells
Study NCT06487858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-R046
Description: Intravenous administration
Study NCT06487858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Intravenous administration
Study NCT06715163 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Contains the same excipients as the DAO tablets but without the diamino oxidase content
Study NCT06715163 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dose 2 (84mg) of DAO
Description: DAO extract is obtained from pea sprout dehydrated powder. Medium dose of DAO administered in this study
Study NCT06715163 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dose 3 (210mg) of DAO
Description: DAO extract is obtained from pea sprout dehydrated powder. Highest dose of DAO administered in this study
Study NCT06450210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: psilocybin trihydrate
Description: Microdoses of psilocybin trihydrate will be administered to participants (1.2 mg, 2.0 mg, 3.0 mg, and 4.2 mg).
Study NCT06450210 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a capsule identical in appearance to the active drug that contains an inactive substance.
Study NCT05181449 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Twin Precision Treatment
Description: Combination of Artificial Intelligence algorithms based on daily sensor input and live nutrition, exercise, sleep and breath coaching to help treat type 2 diabetes
Study NCT06373159 — intervention group
Intervention type: OTHER
Intervention: No study intervention
Description: Retrospective observational study using Real World Data (RWD) in Japan without study intervention
Study NCT06557733 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT06557733 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06557733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EP2/EP4 Antagonist TPST-1495
Description: Given PO
Study NCT06557733 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophagogastroduodenoscopy
Description: Undergo EGD
Study NCT06557733 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastrointestinal Endoscopy
Description: Undergo GI endoscopy
Study NCT06557733 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04682106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3493269
Description: Administered orally.
Study NCT04682106 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.
Study NCT04682106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salcaprozate Sodium
Description: Administered orally.
Study NCT06417892 — intervention group
Intervention type: DRUG
Intervention: PD-1inhibitor
Description: PD-1 antibody was selected according to first-line drug use
Study NCT06417892 — intervention group
Intervention type: DRUG
Intervention: Fruquintinib
Description: a small molecular anti-tumor angiogensis drug
Study NCT06417892 — intervention group
Intervention type: DRUG
Intervention: albumin paclitaxel
Description: a kind of cytotoxic chemotherapy drug
Study NCT05238506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine
Description: Intraoperative intravenous lidocaine infusion.
Study NCT05238506 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline infusion
Description: Intraoperative intravenous normal saline infusion.
Study NCT05496114 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Checklist
Description: A checklist is an aid that outlines assessments or actions systematically. In this study, the checklist outlines interventions to consider during management of a patient with tricyclic antidepressant poisoning. Each checklist will include indications, contra-indications and for medication, dose, route and rate of administration.
Study NCT06209203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lowe-dose ZKY001 eye drops
Description: eye drops
Study NCT06209203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medium-dose ZKY001 eye drops
Description: eye drops
Study NCT06209203 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: eye drops
Study NCT06149676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saccharomyces Boulardii 250 MG [Florastor]
Description: All patients will get the probiotic to be taken daily. If UTI occurs with a sensitive pathogen, we will treat with ciprofloxacin
Study NCT06199921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20mg
Description: Participants will receive oral atorvastatin 20mg daily for 16 weeks
Study NCT06199921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40mg
Description: Participants will receive oral atorvastatin 40mg daily for 16 weeks
Study NCT06199921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 60mg
Description: Participants will receive oral atorvastatin 60 mg daily for 16 weeks
Study NCT06246110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EIK1001
Description: EIK1001 is a Toll like receptor 7/8 (TLR 7/8) agonist
Study NCT06246110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: PD-1 inhibitor
Study NCT06246110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Chemotherapy
Study NCT06246110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Chemotherapy
Study NCT06246110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Chemotherapy
Study NCT05783609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: T-cell bispecific antibody, via subcutaneous injection
Study NCT05783609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Chimeric anti-CD20 monoclonal antibody, via IV infusion
Study NCT04635098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: All participants will be randomly assigned to receive either dexmedetomidine or saline
Study NCT04635098 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: All participants will be randomly assigned to receive either dexmedetomidine or saline
Study NCT05514847 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 81Mg Ec Tab
Description: 81 mg enteric coated aspirin, taken daily from before 14 weeks of gestational age through pregnancy
Study NCT05514847 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Aspirin 81Mg Ec Tab
Description: 81 mg enteric coated aspirin, taken daily from before 14 weeks of gestational age through pregnancy
Study NCT05514847 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 162Mg Ec Tab
Description: 162 mg enteric coated aspirin, taken daily from before 14 weeks of gestational age through pregnancy
Study NCT05187182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CA-4948
Description: Provided by Curis, Inc.
Study NCT05187182 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 240 mg IV on Day 1 of each cycle
Study NCT05187182 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 400 mg IV on Day 1 of every 3 cycles (C1D1, C4D1, C7D1,...) and dosing may continue for a max of 2 years
Study NCT05187182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 6 mg/kg IV loading dose on Cycle 1 Day 1 and 4 mg/kg IV on Day 1 of every subsequent cycle
Study NCT05187182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX7
Description: Standard of care
Study NCT04732403 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Position
Description: The patient will be placed in an angle on the surgical table during cystoscopy.
Study NCT05041023 — intervention group
Intervention type: OTHER
Intervention: Relative section
Description: Relatives are assessed by phone calling with an experienced psychologist at 3 and 6 months after patient's death. Relatives answer to self-questionnaire and 3 scales.~Furthermore, 20 of them are offered to participate in a semi-structured interview with an experienced psychologist, within 6 months to 1 year following the patient's death.
Study NCT05041023 — intervention group
Intervention type: OTHER
Intervention: Caregiver section
Description: Caregivers are self-evaluated within 72 hours after death by questionnaire survey, whose results will remain confidential to the center that included the situation.~Furthermore, 20 of them (10 medical staff and 10 paramedical staff and / or until saturation) are offered to participate in a semi-structured interview with an experienced psychologist.
Study NCT05716139 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Natural Cycle
Description: The participant will be administered a S/C injection of 250mcg r-hCG to assist ovulation and timing of the embryo transfer, when the dominant follicle reaches ≥ 18mm and serum LH \< 20 IU/L, the administration of r-hCG will be in the evening, and the embryo transfer will be scheduled seven days later (window of ± two days). The participant will begin transvaginal progesterone gel (8 %) twice daily starting 36 hrs after the trigger until ten weeks of gestation.
Study NCT05716139 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Artificial Cycle
Description: Estrogen priming with oral estradiol valerate 6mg/day (2mg every 8 hours) starting from cycle D1-D5 after a first TVU. TVU will be performed 10-15 days after beginning estradiol until ET ≥ 7mm, maximum until 21 days. Patients will begin progesterone injection 100mg/day until blastocyst transfer. Frozen embryo transfer will be performed on day 6 +/- 2 days of progesterone administration. After embryo transfer, a supplementation with transvaginal progesterone gel (8 %) twice daily starting from the day of embryo transfer until ten weeks of gestation. Patients will continue Estradiol 2 mg thrice daily until 6 weeks of gestation; then dose tapering will be done to 2 mg twice daily until 9 wks of gestation. From 9th wk the estrogen dose will be tapered further to 2 mg once daily for 10 days before stopping.
Study NCT06328361 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nonoperative surveillance
Description: Clinical and imaging surveillance with digital rectal examination and/or endoscopy, rectal MRI and body CT
Study NCT05424549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reproxalap Ophthalmic Solution (0.25%)
Description: Reproxalap Ophthalmic Solution (0.25%) dosed six times over two consecutive days
Study NCT05424549 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Ophthalmic Solution
Description: Vehicle Ophthalmic Solution dosed six times over two consecutive days
Study NCT04723875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel or docetaxel + Cisplatin or carboplatin
Description: Paclitaxel 135-175mg/m2 over 3 hours or docetaxel 70-75 mg/m2， 30min ＋ Cisplatin 75-80mg/m2 or carboplatin AUC = 5, repeat per 21 days.
Study NCT06413537 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPG601
Description: synthetic small molecule
Study NCT06413537 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04623216 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sabatolimab
Description: Sabatolimab is a solution in vial for IV infusion
Study NCT04623216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine comes in Vial for IV infusion or subcutaneous administration
Study NCT06721442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin (DAPA)
Description: Patients randomized to receive a daily dose of 10 milligrams of dapagliflozin were evaluated to assess the medication's impact on electrocardiographic parameters of repolarization, with focus on its potential to reduce ventricular repolarization prolongation in individuals with type 2 diabetes.
Study NCT06720090 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Light therapy
Description: 5 weeks of light therapy administered via wearable light therapy glasses worn for 1 hour each morning after awakening.
Study NCT06720090 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Light therapy
Description: 5 weeks of light therapy administered via wearable light therapy glasses worn for 1 hour each morning after awakening.
Study NCT06317259 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypoxic breathwork plus music and messaging
Description: Hypoxic breathwork consists of about 5 min of rhythmic breathing in a 4-in/4-out pattern followed by a breath hold on the exhale for about 1-2 min. This is repeated 1-2 times with increasing breath rate up to 2-in/2-out. The audio track also includes dynamic music that accompanies the different stages as well as positive messaging encouraging self-determination.
Study NCT06317259 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hypoxic breathwork only
Description: Hypoxic breathwork consists of about 5 min of rhythmic breathing in a 4-in/4-out pattern followed by a breath hold on the exhale for about 1-2 min. This is repeated 1-2 times with increasing breath rate up to 2-in/2-out. Other than breathing instructions and pacing, the audio track is silent.
Study NCT06317259 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Music and messaging meditation
Description: Music and messaging meditation consists of dynamic music that is engaging and aids focus, as well as positive messaging encouraging self-determination.
Study NCT04267393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986263
Description: Specified dose on specified days
Study NCT04267393 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days
Study NCT04966936 — intervention group
Intervention type: OTHER
Intervention: questionnaires for clinical assessments
Description: Amputee Mobility Predictor, Locomotor Capacity Index, visual analog scale (VAS)
Study NCT04966936 — intervention group
Intervention type: OTHER
Intervention: 2 minute walking test
Description: the individual is asked to walk in his natural course within 2 minutes on a track whose distance is measured beforehand, and at the end of two minutes, the distance he walks will be recorded in meters (m).
Study NCT04966936 — intervention group
Intervention type: OTHER
Intervention: The gait analysis at the motion analysis laboratory.
Description: Temporo-spatial parameters (gait speed (m/s), cadence (step/s), other foot contact (%), double support time (second), single support time (second), stance phase time (sec), swing phase time (sec), stride length (meters)) and kinematic parameters (hip, knee, ankle joint angles (frontal, sagittal, transverse plane), maximum knee flexion angles in the stance and swing phase, velocity-dependent maximum knee flexion angles in the swing phase, knee flexion moments will be compared